Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HE 2200

Drug Profile

HE 2200

Alternative Names: androstenetriol; Reversionex

Latest Information Update: 29 Nov 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Virginia Commonwealth University
  • Developer Hollis-Eden Pharmaceuticals
  • Class Antihyperlipidaemics; Hormones
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Hypercholesterolaemia; Immunodeficiency disorders; Inflammatory bowel diseases; Multiple sclerosis; Neutropenia; Shock

Most Recent Events

  • 18 Aug 2003 Hollis-Eden has completed enrolment in a phase II trial for hypercholesterolaemia
  • 22 Apr 2003 Phase-II clinical trials in Immunodeficiency disorders in USA (SC)
  • 11 Mar 2003 HE 2200 is available for licensing (http://www.holliseden.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top